Diamedica Therapeutics Inc (DMAC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -10,270 | -5,151 | -19,381 | -14,220 | -9,749 |
| Depreciation Amortization | -630 | -321 | -1,193 | -834 | -418 |
| Accounts receivable | -22 | -30 | -287 | -228 | -106 |
| Other Working Capital | -1,240 | -1,687 | 93 | -1,141 | -788 |
| Other Operating Activity | 990 | 536 | 2,040 | 1,507 | 942 |
| Operating Cash Flow | $-11,172 | $-6,653 | $-18,728 | $-14,916 | $-10,119 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 8,953 | 4,217 | -18,275 | -24,402 | -25,608 |
| PPE Investments | -9 | -9 | -24 | -21 | -11 |
| Investing Cash Flow | $8,944 | $4,208 | $-18,299 | $-24,423 | $-25,619 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -3 | -1 | -6 | -5 | -3 |
| Common Stock Issued | 11,754 | N/A | 36,848 | 36,848 | 36,852 |
| Financing Cash Flow | $11,751 | $-1 | $36,842 | $36,843 | $36,849 |
| Beginning Cash Position | 4,543 | 4,543 | 4,728 | 4,728 | 4,728 |
| End Cash Position | 14,066 | 2,097 | 4,543 | 2,232 | 5,839 |
| Net Cash Flow | $9,523 | $-2,446 | $-185 | $-2,496 | $1,111 |
| Free Cash Flow | |||||
| Operating Cash Flow | -11,172 | -6,653 | -18,728 | -14,916 | -10,119 |
| Capital Expenditure | -9 | -9 | -24 | -21 | -11 |
| Free Cash Flow | -11,181 | -6,662 | -18,752 | -14,937 | -10,130 |